Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Thoracic 1Myeloid 1Head & Neck 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 12Colonic Neoplasms 4Neoplasms 3Rectal Neoplasms 2Pancreatic Neoplasms 2Lung Neoplasms 2Gastrointestinal Neoplasms 2Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Thyroid Neoplasms 1Recurrence 1Pancreatic Adenocarcinoma 1Histiocytosis 1Glioma 1Carcinoma, Squamous Cell 1Carcinoma 1

Interventions

Temozolomide 26Bevacizumab 14Radiosurgery 12Radiotherapy 9pembrolizumab 8Carboplatin 8Trastuzumab 6temsirolimus 5Sirolimus 5Erlotinib Hydrochloride 5abemaciclib 4Paclitaxel 4Irinotecan 4Capecitabine 4tipifarnib 3Sorafenib 3Radiation 3Mental Status and Dementia Tests 3Ipilimumab 3Everolimus 3Aminolevulinic Acid 3130-nm albumin-bound paclitaxel 3tucatinib 2pertuzumab 2fludarabine 2durvalumab 2alovudine 2alectinib 2Vorinostat 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Brain Neoplasms × Panitumumab × Clear all
NCT05786924 2026-04-21

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Servier

Phase 1/2 Recruiting
554 enrolled
CNSGastrointestinalHead & NeckMyeloidThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Histiocytosis

NCT03510208 2026-02-09

Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery

Stanford University

Phase 1/2 Recruiting
46 enrolled
CNS

Brain Neoplasms, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡